Latest Management of cancer Stories
Company continues to expand its clinical collaborations with National Comprehensive Cancer Network centers across a broad range of clinically actionable mutations in major cancer types
Lead Immunotherapy Product Candidate GEN-1 to Enter Dose Escalating Clinical Study in the Second Half of 2015 LAWRENCEVILLE, N.J., Jan.
China Food and Drug Administration (CFDA) approves cancer treatment system BEIJING, Dec.
Active Immunotherapy Targets hTERT Gene Associated with 85% of Cancers PLYMOUTH MEETING, Pa., Dec. 18, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc.
Studies Find Potentially Predictive Biomarkers May Lead to Better Patient Outcomes, Bladder Cancer Treatment Options Extend Beyond Chemotherapy Milwaukee, WI
Positive Results of Largest Genomic Study in DCIS Reconfirm Oncotype DX is a Strong, Independent Predictor of Local Recurrence SAN ANTONIO, Dec.
Breast cancer is scary. Its prevalence certainly should make all women aware and active in preventing, catching it early, and taking an active role in treatment. And even though women should have a voice in their treatment, often they simply follow the guidelines set out by their doctors.
SAN ANTONIO, December 11, 2014 /PRNewswire/ -- - The first study in the world combining Reparixin, an oral inhibitor of CXCR1/2, with standard